MedTrace Logo

Comparing Patient Satisfaction With Pataday or Bepreve

NCT01450176 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-09

No results posted yet for this study

Summary

The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).

Conditions

  • Eye Allergies

Interventions

DRUG

Olopatadine hydrochloride 0.2%

1 drop in each eye once daily for 2 weeks

DRUG

Bepotastine besilate ophthalmic solution 1.5%

1 drop in each eye twice daily for 2 weeks

Sponsors & Collaborators

  • McCabe Vision Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-10-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01450176 on ClinicalTrials.gov